• Introduction
  • Why Almac?
  • People
  • Facilities
• Biomarker Discovery and Validation
  • Companion Diagnostics
  • Pharmacodynamic Biomarkers
  • Prognostic tests
  • Drug Repositioning
  • Consultancy
• Bioinformatics Solutions
  • Gene Selection
  • Signature generation
  • Functional analysis
• Genomic services
  • Gene Expression and SNP analysis
  • qPCR and cell line modelling
  • Bioinformatics
• Proprietary Discovery Arrays
  • Unique Content
  • Work with FFPE and fresh frozen tissue
  • Discover Targets, signatures and answers
• Resources
  • Technical Documentation
  • Posters and presentations
  • Publications

Why Almac?

• We are doing it: We have successfully developed our own IVD pipeline from FFPE tissue.
• Enabling Technology: We have a portfolio of proprietary discovery arrays (Xcel™ and Cancer DSA ^®) and the core ability to work with both frozen and FFPE tissue.
• Clinical Trial Design: We have expertise in biomarker clinical trial design, including adaptive strategies, the sequence of interim analyses and modifications, which dynamically modifies the course of a trial.
• Disease knowledge: Our team consists of Molecular Biologists, Medical Oncologists and Bioinformaticians, who all have extensive cancer research expertise and knowledge.

Our core expertise is in the provision of translational genomic based solutions. We have our own IVD tests in development all of which have been developed from FFPE tissue.

We utilise our experience, expertise and our proprietary discovery arrays (Xcel™ and Cancer DSA ^®) to partner with our customers enabling translational genomic solutions.

For each study all customers are assigned a Project Manager who will be your direct contact throughout your study, from experimental design to analysis of data.